Aldeyra Therapeutics (ALDX) Misses Q3 EPS by 1c

Aldeyra Therapeutics (NASDAQ: ALDX) reported Q3 EPS of ($0.27), $0.01 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• TD Cowen Reiterates Buy Rating on NVIDIA (NVDA), 'unlikely to move significantly on earnings'
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance